18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma

Zhejiang University

Status: Completed

Conditions: Lymphoma, Large B-Cell, Diffuse

Treatments: Other: FDG PET radiomic feature evaluation

Study type: Observational

Funder types: Other

Identifiers

NCT04317313

2019-350

Details and patient eligibility

About

This study aims to investigate the prognostic value of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) radiomics in diffuse large B-cell lymphoma (DLBCL) and its additional value to the International Prognostic Index (IPI).

Full description

Several studies have shown that 18F-FDG PET radiomics is predictive of survival in DLBCL. However, to the best of the investigator's knowledge, a multi-feature radiomic signature for prognosis assessment of DLBCL has not yet been described. Furthermore, it remains unclear whether PET-based radiomics could add more prognostic values to the IPI in DLBCL.

This study aims to develop 18F-FDG PET radiomic signature, and investigate whether the radiomic signature could improve the prognostic value of the IPI score in predicting progression-free survival (PFS) and overall survival (OS) in DLBCL.

Enrollment: 152 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. histopathologically confirmed diffuse large B-cell lymphoma (DLBCL);
2. Over 18 years old when diagnosed;
3. Have undergone pre-treatment 18F-FDG PET/CT;
4. Have been initially treated with the combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or R-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin).

Exclusion criteria

1. Have primary central nervous system (CNS) lymphoma or second primary cancer;
2. Have undergone surgical resection;
3. With an incomplete follow-up.

Trial design